(Alliance News) - Mediclinic International PLC on Tuesday said ahead of its annual general meeting that it continues to expect a rise in earnings and revenue for its current financial year.
The London and Johannesburg-listed private healthcare provider said its year-to-date operating performance remains in line with expectations.
As a result, Mediclinic remains confident in posting a rise in earnings before interest, tax, depreciation and amortisation and revenue from all three divisions for the year ending March 31, 2022.
For the 2021 financial year, Ebitda was GBP426 million, on revenue of GBP3.00 billion.
However, Mediclinic warned that pre-Covid-19 seasonal trends which can affect operating performance will return and be reflected in the first half results of Hirslanden, in Switzerland, and Mediclinic Middle East.
The group remains cautious on the full effect Covid-19 will have on its near-term performance, with the ongoing pandemic and the varied pace of vaccine rollout programmes.
Looking ahead, Mediclinic does not anticipate any long-term impediment to Ebitda margins for Hirslanden and Mediclinic Southern Africa returning to pre-pandemic levels.
Meanwhile, Mediclinic Middle East's Ebitda margins are set to gradually increase as it continues to expand in the region, supported by recent upgrade projects in Dubai and Abu Dhabi.
Shares in Mediclinic International were up 0.1% at 284.20 pence on Tuesday in London, while its Johannesburg shares were 0.3% lower at ZAR58.16.
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
